Therapeutic uses of prostaglandin F2α analogues in ocular disease and novel synthetic strategies

Prostaglandins and Other Lipid Mediators

Volumn 104-105, Issue , 2013, Pages 109-121

  Dams, Iwona ^a   Wasyluk, Jaromir ^b   Prost, Marek ^b   Kutner, Andrzej ^a  

^a INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

^b MILITARY INSTITUTE OF AVIATION MEDICINE   (Poland)

Author keywords

Corey lactone; Glaucoma; Ocular hypertension; PGF2 analogues; Prostaglandin synthesis; Side effects

Indexed keywords

BIMATOPROST; FLUPROSTENOL; LATANOPROST; NONSTEROID ANTIINFLAMMATORY AGENT; PROMETHAZINE; PROSTAGLANDIN F2 ALPHA; PROSTANOID; TAFLUPROST; TIMOLOL; TRAVOPROST; UNOPROSTONE; UNOPROSTONE ISOPROPYL ESTER;

ALOPECIA; BEHAVIOR; BLOOD VESSEL PERMEABILITY; CONFERENCE PAPER; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; EYE DISEASE; GLAUCOMA; HAIR LOSS; HEALTH CARE COST; HUMAN; HYPEREMIA; HYPERPIGMENTATION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LEISURE; LOW LEVEL LASER THERAPY; MIOSIS; MOVEMENT (PHYSIOLOGY); NONHUMAN; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; RETINA MACULA CYSTOID EDEMA; SKIN DISCOLORATION; STRUCTURE ACTIVITY RELATION; TRICHIASIS;

AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; DINOPROST; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; PROSTAGLANDINS F; PROSTAGLANDINS F, SYNTHETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84879691074     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2013.01.001     Document Type: Conference Paper

References (199)

1. W.B. Griffin, G. Williams, and J.Y. Crider FP prostaglandin receptors mediating inositol phosphates generation and calcium mobilization in Swiss 3T3 cells: a pharmacological study J Pharmacol Exp Ther 281 1997 845 854 (Pubitemid 27203819)
2. U. Schlötzer-Schrehardt, M. Zenkel, and R.M. Nüsing Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues Invest Ophthalmol Vis Sci 43 2002 1475 1487 (Pubitemid 34462647)
3. P. Mukhopadhyay, L. Bian, and H. Yin Localization of EP1 and FP receptors in human ocular tissues by in situ hybridization Invest Ophthalmol Vis Sci 42 2001 424 428 (Pubitemid 32121474)
4. C.B. Camras, L.Z. Bito, and K.E. Eakins Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits Invest Ophthalmol Vis Sci 16 1977 1125 1134 (Pubitemid 8250543)
5. 2α Curr Eye Res 1 1981 205 209 (Pubitemid 11025673)
6. L.Z. Bito, A. Draga, J. Blanco, and C.B. Camras Long-term maintenance of reduced intraocular pressure by daily topical application of prostaglandins to cat or rhesus monkey eyes Invest Ophthalmol Vis Sci 24 1983 312 319 (Pubitemid 13108839)
7. 2α in the human eye Graefes Arch Clin Exp Ophthalmol 222 1985 139 141
8. 2α and its isopropyl ester on normal and glaucomatous human eyes Prog Clin Biol Res 312 1989 447 458
9. 2α - isopropyl ester eye drops: effects in normal human eyes Br J Ophthalmol 73 1989 419 426 (Pubitemid 19164209)
10. 2α - isopropyl ester applied in multiple doses in ocular hypertensive and glaucomatous patients Ophthalmol 96 1989 1329 1336
11. 2α esters. A double masked cross-over study on normotensive eyes Acta Ophthalmol Scand 68 1990 341 343 (Pubitemid 20210159)
12. G.W. Bean, and C.B. Camras Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences Surv Ophthalmol 53 2008 S69 S84
13. Dams I, Chodyński M, Krupa M, et al. Optically active aldehyde synthons. Polish patent application PL-398388 [9.03.2012].
14. 2α analogues with 13-en-14-ol system. Polish patent application PL-398389 [9.03.2012].
15. J.G. Martynow, J. Jóźwik, and W. Szelejewski A new synthetic approach to high-purity (15R)-latanoprost Eur J Org Chem 4 2007 689 703
16. 2α derivatives. US 7,897,793 B2 [1.03.2011].
17. N.A. Sharif, C.R. Kelly, and J.Y. Crider Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor J Ocul Pharmacol Ther 18 2002 313 324 (Pubitemid 34977654)
18. N.A. Sharif, C.R. Kelly, and J.Y. Crider Human trabecular meshwork cell responses induced by bimatoprost, travoprost,unoprostone, and other FP prostaglandin receptor agonist analogues Invest Ophthalmol Vis Sci 44 2003 715 721 (Pubitemid 36159719)
19. M.R. Hellberg, V.L. Sallee, and M.A. McLaughlin Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist J Ocul Pharmacol Ther 17 2001 421 432 (Pubitemid 33116119)
20. L.B. Cantor Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management Expert Opin Investig Drugs 10 2001 721 731 (Pubitemid 32288189)
21. D.F. Woodward, A.H. Krauss, and J. Chen The pharmacology of bimatoprost (Lumigan) Surv Ophthalmol 45 2001 S337 S345
22. C.B. Camras, N. Sharif, and M. Wax Bimatoprost, the prodrug of a prostaglandin analogue Br J Ophthalmol 92 2008 862 863 (Pubitemid 351839587)
23. C.B. Camras, C.B. Toris, and B. Sjoquist Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery Ophthalmology 111 2004 2193 2198 (Pubitemid 39575588)
24. 2α-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture Invest Ophthalmol Vis Sci 42 2001 1134 1145 (Pubitemid 32381949)
25. Z. Wan, D.F. Woodward, and C.L. Cornell Bimatoprost, prostamide activity, and conventional drainage Invest Ophthalmol Vis Sci 48 2007 4107 4115 (Pubitemid 351261036)
26. C.K. Bahler, K.G. Howell, and C.R. Hann Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments Am J Ophthalmol 145 2008 114 119 (Pubitemid 350265755)
27. N.A. Sharif, I. Kaddour-Djebbar, and A.A. Abdel-Latif Cat iris sphincter smooth-muscle contraction: comparison of FP class prostaglandin analog agonist activities J Ocul Pharmacol Ther 24 2008 152 163 (Pubitemid 351450472)
28. J. Stjernschantz Studies on ocular inflammation and development of a prostaglandin analogue for glaucoma treatment Exp Eye Res 78 2004 759 766 (Pubitemid 38252952)
29. 2+ mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors J Pharmacol Exp Ther 304 2003 238 245 (Pubitemid 36008934)
30. B. Resul, J. Stjernschantz, and G. Selen Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids Surv Ophthalmol 41 1997 S47 S52 (Pubitemid 27154524)
31. N.A. Sharif, J.Y. Crider, and S. Husain Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2p mobilization and MAP kinase activation J Ocul Pharmacol Ther 19 2003 437 455 (Pubitemid 37315132)
32. J.D. Brandt, A.M. VanDenburgh, K. Chen, and S.M. Whitcup Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial Ophthalmology 108 2001 1023 1031 (Pubitemid 32500015)
33. L.M. Doi, L.A. Melo Jr., and J.A. Prata Jr. Effects of the combination of bimatoprost and latanoprost on intraocular pressure in primary open angle glaucoma: a randomised clinical trial Br J Ophthalmol 89 2005 547 549 (Pubitemid 40569707)
34. L.W. Herndon, S.G. Asrani, and G.H. Williams Paradoxical intraocular pressure elevation after combined therapy with latanoprost and bimatoprost Arch Ophthalmol 120 2002 847 849 (Pubitemid 34620371)
35. S.M. Whitcup, L.B. Cantor, A.M. VanDenburgh, and K. Chen A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension Br Ophthalmol 87 2003 57 62 (Pubitemid 36071780)
36. C. Linden, and A. Alm Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity? Curr Eye Res 17 1998 567 572 (Pubitemid 28288655)
37. T. Aung, P.T. Chew, C.C. Yip, and Y.H. Chan A randomized double masked cross over study comparing latanoprost 0.005%with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension Am J Ophthalmol 131 2001 636 644
38. D.L. Eisenberg, and C.B. Camras A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension Drug Saf 20 1999 505 514 (Pubitemid 29296596)
39. H.D. Jampel, J. Bacharach, and W.P. Sheu Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure Am J Ophthalmol 134 2002 863 871 (Pubitemid 35425455)
40. A. Alm, C.B. Camras, and P.G. Watson Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States Surv Ophthalmol 41 1997 S105 S110 (Pubitemid 27154533)
41. D.L. Eisenberg, C.B. Toris, and C.B. Camras Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs Surv Ophthalmol 47 2002 S105 S115 (Pubitemid 35238026)
42. H. Uusitalo, L.E. Pillunat, and A. Ropo Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study Acta Ophthalmol 88 2010 12 19
43. A.G. Konstas, G. Holló, and M. Irkec Diurnal IOP control with bimatoprost versus latanoprost in exfoliative glaucoma: a crossover, observer-masked, three-centre study Br J Ophthalmol 91 2007 757 760 (Pubitemid 46846646)
44. L.B. Cantor, J. Hoop, and L. Morgan Intraocular pressure lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension Br J Ophthalmol 90 2006 1370 1373 (Pubitemid 44702062)
45. R.S. Noecker, M.S. Dirks, and N.T. Choplin A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma Am J Ophthalmol 135 2003 55 63 (Pubitemid 36020425)
46. R.K. Parrish, P. Palmberg, and W.P. Sheu A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study Am J Ophthalmol 135 2003 688 703 (Pubitemid 36457976)
47. S. Gandolfi, S.T. Simmons, and R. Sturm Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension Adv Ther 18 2001 110 121 (Pubitemid 32852703)
48. P.A. Netland, T. Landry, and E.K. Sullivan Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension Am J Ophthalmol 132 2001 472 484 (Pubitemid 32904567)
49. S.A. Gandolfi, and L. Cimino Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are non responders to latanoprost Ophthalmology 110 2003 609 614 (Pubitemid 36262750)
50. D. Ghate, and H.F. Edelhauser Barriers to glaucoma drug delivery J Glaucoma 17 2008 147 156 (Pubitemid 351412405)
51. T.V. Johnson, C.B. Toris, and S. Fan Effects of central corneal thickness on the efficacy of topical ocular hypotensive medications J Glaucoma 17 2008 89 99 (Pubitemid 351412396)
52. J.D. Brandt, J.A. Beiser, and M.O. Gordon Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study Am J Ophthalmol 138 2004 717 722 (Pubitemid 39452917)
53. O. Eyawo, J. Nachega, and P. Lefebvre Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis Clin Ophthalmol 3 2009 447 456
54. F. Aptel, M. Cucherat, and P. Denis Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials J Glaucoma 17 2008 667 673
55. J.W. Cheng, J.P. Cai, and Y. Li A meta-analysis of topical prostaglandin analogs in the treatment of chronic angle-closure glaucoma J Glaucoma 18 2009 652 657
56. N. Li, X.M. Chen, and Y. Zhou Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials Clin Exp Ophthalmol 34 2006 755 764 (Pubitemid 44650150)
57. R. Van der Valk, C.A. Webers, and J.S. Schouten Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials Ophthalmology 112 2005 1177 1185 (Pubitemid 40916921)
58. S. Holmstrom, P. Buchholz, J. Walt, J. Wickstrøm, and M. Aagren Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma Curr Med Res Opin 21 2005 1875 1883 (Pubitemid 41667256)
59. P. Denis, A. Lafuma, and B. Khoshnood A meta-analysis of topical prostaglandin analogues intraocular pressure lowering in glaucoma therapy Curr Med Res Opin 23 2007 601 608 (Pubitemid 46456908)
60. Terminology and Guidelines for Glaucoma. European Glaucoma Society. 3rd Edition, 2008. Dogma. Savona, Italy, p.123.
61. A. Hommer, and F. Kimmich Switching patients from preserved prostaglandin analog monotherapy to preservative-free tafluprost Clin Ophthalmol 5 2011 623 631
62. 2α analogues on endothelin-1-induced impairment of rabbit ocular blood flow: comparison among tafluprost, travoprost, and latanoprost Exp Eye Res 91 2010 853 859
63. H. Kurashima, H. Kurashima, and Y. Asai Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys J Glaucoma 21 2012 123 128
64. K. Kaplowitz, and J.C. Tsai Tafluprost in the treatment of glaucoma Exp Rev Ophthalmol 7 2012 401 407
65. A. Chabi, R. Varma, J. Tsai, R. Lupinacci, J. Pigeon, C. Baranak, L. Noble, C. Lines, and T.W. Ho Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension Am J Ophthalmol 153 2012 1187 1196
66. R.A. Schumer, C.B. Camras, and A.K. Mandahl Putative side effects of prostaglandin analogs Surv Ophthalmol 47 2002 S219 S230 (Pubitemid 35232235)
67. J. Stjernschantz, S.F. Nilsson, and M. Astin Vasodynamic and angiogenic effects of eicosanoids in the eye Prog Clin Biol Res 312 1989 155 170
68. 2α and latanoprost acid on isolated ocular blood vessels in vitro J Ocul Pharmacol Ther 14 1998 119 128
69. 2α- and latanoprost acid-induced relaxation of submental veins Eur J Pharmacol 340 1997 195 201 (Pubitemid 28022642)
70. R.A. Lawrence, and R.L. Jones Investigation of the prostaglandin E (EP-) receptor subtype mediating relaxation of the rabbit jugular vein Br J Pharmacol 105 1992 817 824
71. 2α-induced ocular hyperemia Exp Eye Res 59 1994 401 407
72. 2α-induced ocular surface hyperemia by sensory nerves in rabbits Curr Eye Res 16 1997 886 890 (Pubitemid 27410071)
73. A. Alm, and J. Stjernschantz Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group Ophthalmology 102 1995 1743 1752 (Pubitemid 26004426)
74. J. Chen, T. Dinh, and D.F. Woodward Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy Cardiovasc Drug Res 23 2005 231 246 (Pubitemid 41572015)
75. P. Watson, and J. Stjernschantz A six-month, randomized, double masked study comparing latanoprost with timolol in open angle glaucoma and ocular hypertension. The Latanoprost Study Group Ophthalmology 103 1996 126 137 (Pubitemid 26046169)
76. J.T. Whitson, and W.M. Petroll Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and/or antihypertensive agents Adv Ther 29 2012 874 888
77. Seibold LK, Ammar DA, Kahook Malik Y. Acute effects of glaucoma medications and benzalkonium chloride on pre-adipocyte proliferation and adipocyte cytotoxicity in vitro. Curr Eye Res 2012, Oct 18 [Epub ahead of print].
78. E. Milla, O. Stribu, A. Rey, S. Duch, O. Buchacra, A. Robles, C. Navarro, R. Gil, and J.M. Corder Spanish multicenter tafluprost tolerability study Br J Ophthalmol 96 2012 826 831
79. P. Daull, R. Buggage, G. Lambert, M.O. Faure, J. Serle, R.F. Wang, and J.S. Garrigue A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models J Ocul Pharmacol Ther 28 2012 515 523
80. H. Liang, F. Brignole-Baudouin, and L. Riancho Reduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium- preserved travoprost or latanoprost ophthalmic solutions Ophthalmic Res 48 2012 89 101
81. K. Inoue, M. Iwasa, M. Wakakura, and G. Tomita Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma Clin Ophthalmol 6 2012 1315 1319
82. R. Araki, M. Nakashima, M. Teshima, Y. Owaki, M. Nakashima, M. Uematsu, T. Kitaoka, T. Nakamura, T. Kitahara, and H. Sasaski Investigation of protective effects of sodium hyaluronate eyedrop against corneal epithelial disorders using an electrophysiological method J Ocul Pharmacol Ther 28 2012 251 258
83. A.G. Konstas, V.P. Kozobolis, and I.E. Katsimpris Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients Ophthalmology 114 2007 653 657 (Pubitemid 46483692)
84. C.J. Brittain, R. Saxena, and A. Waldock Prospective comparative switch study from timolol 0.5% and latanoprost 0.005% to bimatoprost 0.03% Adv Ther 23 2006 68 73
85. A.G. Konstas, J.M. Katsimbris, and N. Lallos Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients Ophthalmology 112 2005 262 266 (Pubitemid 40202562)
86. S.T. Simmons, M.S. Dirks, and R.J. Noecker Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials Adv Ther 21 2004 247 262 (Pubitemid 39524902)
87. W.C. Stewart, A.E. Kolker, and J.A. Stewart Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost Am J Ophthalmol 135 2003 314 320 (Pubitemid 36279517)
88. T. Tsumura, K. Yoshikawa, H. Suzumura, T. Kimura, S. Sasaki, I. Kimura, and R. Takeda Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events Clin Ophthalmol 6 2012 1547 1552
89. F. Honrubia, J. García-Sánchez, and V. Polo Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials Br J Ophthalmol 93 2009 316 321
90. L.W. Herndon, R.D. Williams, and M. Wand Increased periocular pigmentation with ocular hypotensive lipid use in African Americans Am J Ophthalmol 135 2003 713 715 (Pubitemid 36457983)
91. M. Wand, R. Ritch, and E.K. Isbey Jr. Latanoprost and periocular skin color changes Arch Ophthalmol 119 2001 614 615 (Pubitemid 32293569)
92. M. Centofanti, F. Oddone, and S. Chimenti Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy Am J Ophthalmol 142 2006 1059 1060 (Pubitemid 44853893)
93. M. Doshi, D.P. Edward, and S. Osmanovic Clinical course of bimatoprost-induced periocular skin changes in Caucasians Ophthalmology 113 2006 1961 1967 (Pubitemid 44635710)
94. F. Feletti, C. Vincenzi, and M. Pazzaglia Periocular pigmentation associated with use of travoprost for the treatment of alopecia areata of the eyelashes J Eur Acad Dermatol Venereol 21 2007 421 423
95. G.D. Galloway, T. Eke, and D.C. Broadway Periocular cutaneous pigmentary changes associated with bimatoprost use Arch Ophthalmol 123 2005 1609 1610 (Pubitemid 41626702)
96. R. Kapur, S. Osmanovic, and S. Toyran Bimatoprost induced periocular skin hyperpigmentation: histopathological study Arch Ophthalmol 123 2005 1541 1546 (Pubitemid 41626690)
97. G. Hollo The side effects of the prostaglandin analogues Expert Opin Drug Saf 6 2007 45 52 (Pubitemid 46150523)
98. K. Inoue, M. Shiokawa, R. Higa, M. Sugahara, T. Soga, M. Wakakura, and G. Tomita Adverse periocular reactions to five types of prostaglandin analogs Eye 26 2012 1465 1472
99. Z.A. Abdel-Malek, V.B. Swope, N. Amornsiripanitch, and J.J. Nordlund In vitro modulation of proliferation and melanization of S91 melanoma cells by prostaglandins Cancer Res 47 1987 3141 3146 (Pubitemid 17082638)
100. P.K. Sodhi, L. Verma, and S.K. Ratan Increased periocular pigmentation with ocular hypotensive lipid use in African Americans Am J Ophthalmol 137 2004 783 (Pubitemid 38446711)
101. E. Arranz-Marquez, M.A. Teus, and M.A. Saornil Analysis of irises with a latanoprost-induced change in iris color Am J Ophthalmol 138 2004 625 630 (Pubitemid 39420492)
102. K.P. Cracknell, I. Grierson, and P. Hogg Morphometric effects of long-term exposure to latanoprost Ophthalmology 114 2007 938 948
103. K.P. Cracknell, I. Grierson, and P. Hogg Latanoprost induced iris darkening: a morphometric study of human peripheral iridectomies Exp Eye Res 77 2003 721 730 (Pubitemid 37373586)
104. M. Wand Latanoprost and hyperpigmentation of eyelashes Arch Ophthalmol 115 1997 1206 1208 (Pubitemid 27387964)
105. T. Chiba, K. Kashiwagi, and K. Ishijima A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost Jpn J Ophthalmol 48 2004 141 147 (Pubitemid 38453787)
106. K. Inoue, M. Wakakura, and J. Inoue Adverse reaction after use of latanoprost in Japanese glaucoma patients Nippon Ganka Gakkai Zasshi 110 2006 581 587
107. M.A. Johnstone Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost Am J Ophthalmol 132 2001 472 484
108. B.E. McCarey, B.M. Kapik, F.E. Kane Unoprostone Monotherapy Study Group Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15% Ophthalmology 111 2004 1480 1488 (Pubitemid 39030799)
109. K. Modschiedler, P. von den Driesch, and R. Paus Hyperpigmentosis and hypertrichosis of the eyelids after use of bimatoprost eye drops J Dtsch Dermatol Ges 3 2005 276 277 (Pubitemid 40477159)
110. C.L. Morris, S. Stinnett, and J. Woodward The role of bimatoprost eyelash gel in chemotherapy-induced madarosis: an analysis of efficacy and safety Int J Trichology 3 2011 84 91
111. J.A. Woodward, C.J. Haggerty, and S.S. Stinnett Bimatoprost 0.03% gel for cosmetic eyelash growth and enhancement J Cosmet Dermatol 9 2010 96 102
112. S. Smith, S. Fagien, S.M. Whitcup, F. Ledon, C. Somogyi, E. Weng, and F.C. Beddingfield Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study J Am Acad Dermatol 66 2012 801 806
113. U. Blume-Peytavi, S. Loennfors, K. Hillmann, and N. Garcia Bartels A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment bylatanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia J Am Acad Dermatol 66 2012 794 800
114. E.S. Schweiger, L. Pinchover, and R.M. Bernstein Topical bimatoprost for the treatment of eyebrow hypotrichosis J Drugs Dermatol 11 2012 106 108
115. W. Bearden, and R. Anderson Trichiasis associated with prostaglandin analog use Ophthal Plast Reconstr Surg 20 2004 320 322 (Pubitemid 38971789)
116. R.J. Casson, and D. Selva Lash ptosis caused by latanoprost Am J Ophthalmol 139 2005 932 933 (Pubitemid 40614793)
117. L.Z. Bito Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect Surv Ophthalmol 41 1997 1 14
118. P.J. Wistrand, J. Stjernschantz, and K. Olsson The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color Surv Ophthalmol 41 1997 S129 S138 (Pubitemid 27154537)
119. I. Grierson, M. Jonsson, and K. Cracknell Latanoprost and pigmentation Jpn J Ophthalmol 48 2004 602 612 (Pubitemid 40104633)
120. A. Alm, J. Schoenfelder, and J. McDermott A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma Arch Ophthalmol 122 2004 957 965 (Pubitemid 39037958)
121. T. Chiba, K. Kashiwagi, and N. Chiba Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study Br J Ophthalmol 87 2003 956 959 (Pubitemid 36936289)
122. M. Suzuki, H.K. Mishima, and K. Masuda Efficacy and safety of latanoprost eye drops for glaucoma treatment: a 1-year study in Japan Jpn J Ophthalmol 44 2000 33 38 (Pubitemid 30029132)
123. M.A. Teus, E. Arranz-Márquez, and P. Lucea-Suescun Incidence of iris colour change in latanoprost treated eyes Br J Ophthalmol 86 2002 1085 1088
124. C. Costagliola, A. Del Prete, and M. Verolino Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by β-blockers twice daily: a 3-year follow-up. Experience and incidence of side effects in a prospective study on 76 patients Graefes Arch Clin Exp Ophthalmol 240 2002 379 386 (Pubitemid 36075612)
125. D.N. Hu, J. Stjernschantz, and S.A. McCormick Effect of prostaglandins A(2), E(1), F(2 alpha) and latanoprost on cultured human iridal melanocytes Exp Eye Res 70 2000 113 120 (Pubitemid 30046881)
126. K.U. Loefïer, M. Sahm, and M. Spitznas Short-time application of latanoprost does not stimulate melanogenesis in bovine ocular melanin-containing cells in vitro Ophthalmic Res 33 2001 102 106 (Pubitemid 32221230)
127. N. Pfeiffer, I. Grierson, and H. Goldsmith Histological effects in the iris after 3 months of latanoprost therapy: the Mainz 1 study Arch Ophthalmol 119 2001 191 196 (Pubitemid 32147925)
128. N. Pfeiffer, I. Grierson, and H. Goldsmith Fine structural evaluation of the iris after unilateral treatment with latanoprost in patients undergoing bilateral trabeculectomy Arch Ophthalmol 121 2003 23 31 (Pubitemid 36401762)
129. D.M. Albert, R.E. Gangnon, and M.L. Zimbric Study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients Arch Ophthalmol 122 2004 1680 1685 (Pubitemid 39473414)
130. K.P. Cracknell, I. Grierson, and P. Hogg Melanin in the trabecular meshwork is associated with age, POAG but not Latanoprost treatment. A masked morphometric study Exp Eye Res 82 2006 986 993
131. Y. Nakamura, Y. Nakamura, S. Morine-Shinjo, H. Sakai, and S. Sawaguchi Assessment of chamber angle pigmentation during long term latanoprost treatment for open-angle glaucoma Acta Ophthalmol Scand 82 2004 158 160 (Pubitemid 38515370)
132. I.C. Lai, M.T. Kuo, and L.M.C. Teng Iris pigment epithelial cyst induced by topical administration of latanoprost Br J Ophthalmol 87 2003 366 (Pubitemid 36313003)
133. D.J. Browning, S.L. Perkins, and K.K. Lark Iris cyst secondary to latanoprost mimicking iris melanoma Am J Ophthalmol 135 2003 419 421 (Pubitemid 36279546)
134. J. Krohn, and V.K. Hove Iris cyst associated with topical administration of latanoprost Am J Ophthalmol 127 1999 91 93 (Pubitemid 29036626)
135. A.L.C. Tam, N. Gupta, and Z. Zhang Latanoprost stimulates lymphatic drainage from the mouse eye ARVO 2012, poster no. 1749 2012
136. K. Miyake, I. Ota, and K. Maekubo Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias Arch Ophthalmol 117 1999 34 40 (Pubitemid 29056717)
137. R.E. Warwar, J.D. Bullock, and D. Ballal Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients Ophthalmology 105 1998 263 268 (Pubitemid 28090830)
138. R.D. Fechtner, A.S. Khouri, and T.J. Zimmerman Anterior uveitis associated with latanoprost Am J Ophthalmol 126 1998 37 41 (Pubitemid 28341216)
139. M.B. Horsley, and T.C. Chen The use of prostaglandin analogs in the uveitic patient Semin Ophthalmol 26 2011 285 289
140. N.N. Markomichelakis, A. Kostakou, and I. Halkiadakis Efficacy and safety of latanoprost in eyes with uveitic glaucoma Graefes Arch Clin Exp Ophthalmol 247 6 2009 775 780
141. A. Pollack, H. Leiba, and A. Bukelman Cystoid macular oedema following cataract extraction in patients with diabetes Br J Ophthalmol 76 1992 221 224
142. M. Wand, and A.R. Gaudio Cystoid macular edema associated with ocular hypotensive lipids Am J Ophthalmol 133 2002 403 405 (Pubitemid 34171593)
143. J.A. Rowe, M.G. Hattenhauer, and D.C. Herman Adverse side effects associated with latanoprost Am J Ophthalmol 124 1997 683 685 (Pubitemid 27469245)
144. S.E. Moroi, M.S. Gottfredsdottir, and M.T. Schteingart Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension Ophthalmology 106 1999 1024 1029 (Pubitemid 30191566)
145. R.S. Ayyala, D.A. Cruz, and C.E. Margo Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes Am J Ophthalmol 126 1998 602 604 (Pubitemid 28475931)
146. M. Furuichi, T. Chiba, and K. Abe Cystoid macular edema associated with topical latanoprost in glaucomatous eyes with a normally functioning blood-ocular barrier J Glaucoma 10 2001 233 236 (Pubitemid 32553588)
147. M.C. Lima, A. Paranhos Jr., and S. Salim Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost J Glaucoma 9 2000 317 321 (Pubitemid 32429202)
148. M. Wand, A.R. Gaudio, and M.B. Shields Latanoprost and cystoid macular edema in high-risk aphakic or pseudophakic eyes J Cataract Refract Surg 27 2001 1397 1401 (Pubitemid 32889317)
149. D.M. Kroll, and J.S. Schuman Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma Am J Ophthalmol 133 2002 401 403 (Pubitemid 34171592)
150. M. Wand, C.M. Gilbert, and T.J. Liesegang Latanoprost and herpes simplex keratitis Am J Ophthalmol 127 1999 602 604 (Pubitemid 29215774)
151. P. Ekatomatis Herpes simplex dendritic keratitis after treatment with latanoprost for primary open angle glaucoma Br J Ophthalmol 85 2001 1008 1009 (Pubitemid 32706180)
152. M.T. Kothari, B.K. Mehta, and N.S. Asher Recurrence of bilateral herpes simplex virus keratitis following bimatoprost use Indian J Ophthalmol 54 2006 47 48 (Pubitemid 43363579)
153. H.E. Kaufman, E.D. Varnell, and H.W. Thompson Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit Am J Ophthalmol 127 1999 531 536 (Pubitemid 29215763)
154. G. Bean, G. Reardon, and T.J. Zimmerman Association between ocular herpes simplex virus and topical ocular hypotensive therapy J Glaucoma 13 2004 361 364 (Pubitemid 39281575)
155. J.H. Lass, G.L. Eriksson, L. Osterling, C.V. Simpson Latanoprost Corneal Effects Study Group Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: a double-masked, randomized, one-year study Ophthalmology 108 2001 264 271 (Pubitemid 32115954)
156. T. Schlote, A. Tzamalis, and M. Kynigopoulos Central corneal thickness during treatment with travoprost 0.004% in glaucoma patients J Ocul Pharmacol Ther 25 2009 459 462
157. J.Y. You, and B.J. Cho Effect of latanoprost on central corneal thickness in unilateral normal-tension glaucoma J Ocul Pharmacol Ther October 2012 [Epub ahead of print]
158. Y. Zhong, X. Shen, and J. Yu The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness Cornea 30 2011 861 864
159. E. Sen, Nalcacioglu P, and A. Yazici Comparison of the effects of latanoprost and bimatoprost on central corneal thickness J Glaucoma 17 2008 398 402
160. R.A. Guedes, V.M. Guedes, S.M. Freitas, and A. Chaoubah Quality of life of glaucoma patients under medical therapy with different prostaglandins Clin Ophthalmol 6 2012 1749 1753
161. 2 (dl) J Am Chem Soc 91 1969 5675 5677
162. 2 as the naturally occurring forms J Am Chem Soc 92 1970 397 398
163. 2 (natural forms) from a common synthetic intermediate J Am Chem Soc 92 1970 2586 2587
164. E.J. Corey The logic of chemical synthesis: multistep synthesis of complex carbogenic molecules (Nobel lecture) Angew Chem Int Ed Engl 30 1991 455 465
165. E.J. Corey, and X.-M. Cheng The logic of chemical synthesis 1989 John Wiley & Sons New York p. 255-6
166. B. Resul, J. Stjernschantz, and K. No Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents J Med Chem 36 1993 243 248 (Pubitemid 23060092)
167. 3H]-travoprost: isopropyl ester prodrug of a selective prostaglandin FP receptor agonist J Labelled Compd Radiopharm 44 2001 173 183 (Pubitemid 32199836)
168. P.W. Collins, and S.W. Djuric Synthesis of therapeutically useful prostaglandin and prostacyclin analogs Chem Rev 93 1993 1533 1564
169. 2α isopropyl ester: potential antiglaucoma agents J Med Chem 38 1995 289 304
170. 2α derivative Tetrahedron Lett 45 2004 1527 1529 (Pubitemid 38134343)
171. P. Klimko, M. Hellberg, and M. McLaughlin Bioorg Med Chem 12 2004 3451 3469
172. 2α Tetrahedron Lett 37 1996 779 782
173. 2 receptor agonist Bioorg Med Chem Lett 15 2005 1873 1876 (Pubitemid 40380750)
174. E.J. Corey, S.M. Albonico, and U. Koelliker New reagents for stereoselective carbonyl reduction. Improved synthetic route to the primary prostaglandins J Am Chem Soc 93 1971 1491 1493
175. E.J. Corey, K.B. Becker, and R.K. Varma Efficient generation of the 15S configuration in prostaglandin synthesis. Attractive interactions in stereochemical control of carbonyl reduction J Am Chem Soc 94 1972 8616 8618
176. E.J. Corey, R.K. Bakshi, and S. Shibata A stable and easily prepared catalyst for the enantioselective reduction of ketones. Applications to multistep synthesis J Am Chem Soc 109 1987 7925 7926
177. C. Aswathanarayanappa, E. Bheemappa, and Y.D. Bodke Diastereoselective reduction of the enone intermediate of travoprost Org Process Res Dev 15 2011 1085 1087
178. Gutman A, Nisnevich G, Etinger M, et al. Process for the preparation of prostaglandin derivatives. US 7,166,730 B2 [23.01.2007].
179. G. Zanoni, A. D'Alfonso, and A. Porta The Meyer-Schuster rearrangement: a new synthetic strategy leading to prostaglandins and their drug analogs, bimatoprost and latanoprost Tetrahedron 66 2010 7472 7478
180. Bowler J, Crossley NS. Cyclopentane derivatives. GB 1350971 [24.04.1974].
181. 3-mediated reactions of a sulphone and aldehydes Tetrahedron Lett 26 1985 5597 5600
182. 3-mediated reaction of a sulphone with aldehydes. A method for stereospecific construction of prostaglandin ω-chain Tetrahedron 44 1988 4989 4998
183. T. Boulton, D. Brick, and M.E. Fox Synthesis of the potent antiglaucoma agent, travoprost Org Process Res Dev 6 2002 138 145
184. S. Das, S. Chandrasekhar, and J.S. Yadav Recent developments in the synthesis of prostaglandins and analogues Chem Rev 107 2007 3286 3337 (Pubitemid 47177112)
185. 2 isoprostane J Org Chem 67 2002 4346 4351 (Pubitemid 34619845)
186. (+) - method de synthese generale de doubles liaisons Tetrahedron Lett 14 1973 4833 4836
187. P.J. Kocieński, B. Lythgoe, and S. Ruston Scope and stereochemistry of an olefin synthesis from β-hydroxysulphones J Chem Soc Perkin Trans 1 1978 829-34, 838
188. P.J. Kocieński, B. Lythgoe, and I. Waterhouse The influence of chain-branching on the steric outcome of some olefin-forming reactions J Chem Soc Perkin Trans 1 1980 1045 1050
189. P.J. Kocieński Recent sulphone-based olefination reactions Phosphorus Sulfur Silicon Relat Elem 24 1985 97 127
190. P.R. Blakemore, W.J. Cole, and P.J. Kocieński A stereoselective synthesis of trans-1,2-disubstituted alkenes based on the condensation of aldehydes with metallated 1-phenyl-1H-tetrazol-5-yl sulfones Synlett 1 1998 26 28 (Pubitemid 128693868)
191. P.R. Blakemore, D.K.H. Ho, and W.M. Nap Ethyl (benzothiol-2-ylsulfonyl) acetate: a new reagent for the stereoselective synthesis of α β-unsaturated esters from aldehydes Org Biomol Chem 3 2005 1365 1368 (Pubitemid 40644162)
192. W.L. Nelson, J.E. Wennerstrom, and S.R. Sankar Absolute configuration of glycerol derivatives. Synthesis and cupra A circular dichroism spectra of some chiral 3-aryloxy-1,2-propanediols and 3-aryloxy-1-amino-2-propanols J Org Chem 42 1977 1006 1012 (Pubitemid 8106560)
193. 1 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones J Org Chem 48 1983 4155 4156
194. B.M. Trost Chemical chameleons. Organosulfones as synthetic building blocks Bull Chem Soc Jpn 61 1988 107 124
195. N.S. Simpkins The chemistry of vinyl sulphones Tetrahedron 46 1990 6951 6984
196. I.R. Baldwin, and R.J. Whitby Total synthesis of (±)- acetoxyodontoschismenol using zirconium chemistry Chem Commun 22 2003 2786 2787 (Pubitemid 37467894)
197. B.M. Trost, H.C. Arndt, and P.E. Strege Desulfonylation of aryl alkyl sulfones Tetrahedron Lett 17 1976 3477 3478
198. J.T. Whitson, W.B. Trattler, and C. Matossian Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension J Ocul Pharmacol Ther 26 2010 287 292
199. T.J. Zimmerman, S.R. Hahn, and L. Gelb The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence J Ocul Pharmacol Ther 25 2009 145 152